Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | LCK | P06239 | 5/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039516 | 0.78 | DYRK1A (0.36) | DYRK1BGABRA5LCK | |
| SCHEMBL29893472 | 0.78 | PARP1 (0.47) | TYRO3DYRK1BCHEK1RPS6KA5 | |
| SCHEMBL4039665 | 0.71 | DAO (0.47) | GABRA5LCKDAO | |
| SCHEMBL4038259 | 0.70 | GRIA1 (0.38) | GABRA5CHEK1CHEK2CDK1GSK3B | |
| SCHEMBL29235248 | 0.70 | AURKA (0.41) | TYRO3DYRK1BGABRA5LCKCHEK1 | |
| SCHEMBL10006861 | 0.68 | PDE3B (0.47) | TYRO3DYRK1B | |
| SCHEMBL29349996 | 0.68 | PDE3B (0.47) | TYRO3DYRK1B | |
| SCHEMBL2468642 | 0.67 | DAO (0.46) | GABRA5DAO | |
| SCHEMBL9035348 | 0.66 | TYRO3 (0.72) | TYRO3DYRK1BDAO | |
| SCHEMBL4038168 | 0.66 | CHEK1 (0.41) | GABRA5LCKCHEK1CHEK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1066286-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-29 | — | — | EP | disclosed |
| US-5990109-A | NOVEL COMPOUNDS, METHODS OF THEIR SYNTHESIS, AND THEIR USE IN TREATING VARIOUS TYROSINE KINASE-ASSOCIATED IMMUNOLOGICAL DISORDERS, SUCH AS RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, GRAFT VS. HOST DISEASE, LUPUS, PSORIASIS AND ASTHMA | BRISTOL-MYERS SQUIBB CO. (US) | 1999-11-23 | — | — | US | disclosed |